| Q48191350 | (11)C-methylaminoisobutyric acid (MeAIB) PET for evaluation of prostate cancer: compared with (18)F-fluorodeoxyglucose PET. |
| Q64886296 | Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. |
| Q53476667 | Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. |
| Q40585826 | Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. |
| Q37045608 | Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories |
| Q37470233 | Cancer's craving for sugar: an opportunity for clinical exploitation |
| Q40394810 | Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination |
| Q42494827 | Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue |
| Q40448619 | Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer. |
| Q64100343 | Epidemiology of Prostate Cancer |
| Q36881828 | Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| Q36186589 | Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier |
| Q39935802 | Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy |
| Q37482653 | Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation |
| Q46411715 | Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. |
| Q37352995 | FDG PET in Prostate Cancer |
| Q36472442 | Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer |
| Q57107963 | Fructose and prostate cancer: toward an integrated view of cancer cell metabolism |
| Q34749930 | Functional analyse of GLUT1 and GLUT12 in glucose uptake in goat mammary gland epithelial cells |
| Q43941119 | Functional characterization of the human facilitative glucose transporter 12 (GLUT12) by electrophysiological methods |
| Q37623840 | GLUT1 as a therapeutic target in hepatocellular carcinoma |
| Q42787448 | GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. |
| Q47438548 | GLUT1 regulates cell glycolysis and proliferation in prostate cancer. |
| Q50066658 | GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. |
| Q51248960 | GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors? |
| Q39463185 | Glucosamine-linked near-infrared fluorescent probes for imaging of solid tumor xenografts |
| Q28201190 | Glucose transporter GLUT12-functional characterization in Xenopus laevis oocytes |
| Q40519057 | Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity |
| Q92028694 | Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy |
| Q38575844 | Glycosylated Porphyrins, Phthalocyanines, and Other Porphyrinoids for Diagnostics and Therapeutics. |
| Q38067388 | Hepatic expression and cellular distribution of the glucose transporter family. |
| Q37341858 | Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle |
| Q50951551 | Inverted methoxypyridinium phthalocyanines for PDI of pathogenic bacteria. |
| Q39003083 | Is There Use for FDG-PET in Prostate Cancer? |
| Q36300793 | Linking obesogenic dysregulation to prostate cancer progression |
| Q27025766 | Lipid metabolism in prostate cancer |
| Q41573017 | Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13C Stable Isotope-Resolved Metabolomic Study |
| Q38773938 | Methyl 6-Amino-6-deoxy-d-pyranoside-Conjugated Platinum(II) Complexes for Glucose Transporter (GLUT)-Mediated Tumor Targeting: Synthesis, Cytotoxicity, and Cellular Uptake Mechanism |
| Q37325974 | Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. |
| Q37207397 | Molecular imaging of prostate cancer: a concise synopsis |
| Q40419487 | Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia |
| Q37779733 | Potential role of sugar transporters in cancer and their relationship with anticancer therapy |
| Q37746128 | Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients |
| Q50057843 | Prostate cancer diagnosis and characterization with mass spectrometry imaging |
| Q36836615 | RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research |
| Q28266516 | Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy |
| Q37463413 | Revisiting the seed and soil in cancer metastasis |
| Q46715175 | Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater |
| Q34316993 | Similar [DE]XXXL[LI] motifs differentially target GLUT8 and GLUT12 in Chinese hamster ovary cells |
| Q36152297 | The applications of corrected standardized uptake values in the diagnosis of peripheral lung lesions |
| Q47379977 | The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? |
| Q38821546 | The emerging role of obesity, diet and lipid metabolism in prostate cancer |
| Q38079455 | The facilitative glucose transporter GLUT12: what do we know and what would we like to know? |
| Q40205322 | The impact of prolonged hyperinsulinaemia on glucose transport in equine skeletal muscle and digital lamellae. |
| Q53267697 | The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level |
| Q34204238 | Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters |
| Q38752612 | Vacuolar H+-ATPase in the nuclear membranes regulates nucleo-cytosolic proton gradients |
| Q53532559 | [Advancement of PET and PET/CT in prostate carcinoma]. |